News Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance Continue Reading Previous New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral ClearanceNext Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance Related Stories News Walmart Sparky Optimisation: What Brands Should Do to Get Recommended as Sparky Users Spend 40% More News From Non-Electric to Smart Toilets: Australian Bidet Brand Conor Expands Into New Zealand News CALB (03931.HK) Reports Strong Growth in 1H 2026 Results, with Net Profit Increasing Significantly Year-on-Year by 102.2% News CIMC Group Announces 2026 Interim Results News Laifual (03952.HK) Announces 2026 Interim Results News Mobius Social Stock Investment Simulation Competition Officially Launches, Registration Now Opens
